Phase 2
Completed N=29
Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
Source: ClinicalTrials.gov NCT00100165 ↗Enrolled (actual)
29
Serious AEs
100.0%
Results posted
Jan 2020
Primary outcomePrimary: Neurocognitive Performance — 4.5; 6.1; 7.6 t-score change from baseline
Summary
The study hypothesis is that 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A), an orally administered nicotinic cholinergic agonist, will improve attention and other neuropsychological dysfunctions in schizophrenia, leading to improved psychosocial outcome.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Neurocognitive Performance |
4.5; 6.1; 7.6 | — |
| SECONDARY Scale for the Assessment of Negative Symptoms (SANS) |
6.1; 7.6; 4.6 | — |
Eligibility Criteria
Inclusion Criteria
- Schizophrenia
- Currently treated with neuroleptic drugs
Exclusion Criteria
- Treatment with clozapine;
- Head injury or neurological condition;
- Cardiovascular disease;
- Substance abuse or dependence, including nicotine
Data sourced from ClinicalTrials.gov (NCT00100165). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.